



**OPTOS PLC**  
(the “Company”)

**AGM RESULTS**

**LONDON, UK, 23 February 2011 – Optos plc (LSE: OPTS)**, a leading retinal imaging company, today announces that all of the Resolutions set out in the Company’s Notice of Annual General Meeting (the “Meeting”) issued to shareholders on 24 January 2011 were passed by shareholders at the Meeting held earlier today. In accordance with LR 9.6.2R, Resolutions 7-12 (detailed below) constituted special business of the Company and electronic copies of these Resolutions have been submitted to the National Storage Mechanism (“NSM”) and will shortly be available for inspection at [www.hemscott.com/nsm.do](http://www.hemscott.com/nsm.do).

**Presentation**

Mr Roy Davis, Chief Executive Officer, provided a business update at the Meeting and a copy of his presentation has been made available on the Company’s website.

**Proxy Voting Results**

Proxy voting results in respect of Ordinary Resolutions 1-9 and Special Resolutions 10-12 are shown below and, in accordance with the Combined Code D.2.2, the voting results are being made available on the Company’s web site.

RESOLUTION	TOTAL	FOR	%	AGAINST	%	DISCRETIONARY	WITHHELD <sup>1</sup>
1	44,119,483	44,115,118	100.00	0	0.00	4,365	0
2	44,119,482	31,943,636	72.40	6,038,698	13.70	4,965	6,132,183
3	44,119,483	43,861,295	99.40	229,473	0.50	4,365	24,350
4	44,119,483	44,086,419	99.90	4,349	0.00	4,365	24,350
5	44,119,483	42,787,409	97.00	1,300	0.00	4,965	1,325,809
6	44,119,483	44,112,536	100.00	1,982	0.00	4,965	0
7	44,119,482	31,555,838	71.50	8,265,457	18.70	4,965	4,293,222
8	44,119,483	44,109,725	100.00	0	0.00	4,965	4,793
9	44,119,483	44,087,793	99.90	1,931	0.00	4,965	24,794
10	44,119,483	42,788,601	97.00	444	0.00	4,365	1,326,073
11	44,119,483	43,830,559	99.30	229,917	0.50	4,365	54,641
12	44,119,483	42,999,795	97.50	1,115,323	2.50	4,365	0

**Ordinary Resolutions**

1. To receive and adopt the annual accounts of the Company for the financial year ended 30 September 2010 together with the Directors’ and Auditors Reports thereon.
2. To approve the Directors’ Remuneration Report for the financial year ended 30 September 2010.
3. To re-appoint Ernst & Young LLP as Auditors of the Company.
4. To authorise the Directors of the Company to determine the remuneration of the Auditors.
5. To elect Peter Herbert KEHOE as a Director of the Company.
6. To re-elect Barry Michael ROSE as a Director of the Company.
7. To approve and adopt the Optos plc Deferred Bonus Plan.
8. To approve the Trust Deed to establish the Optos plc Employee Benefit Trust and to authorise the establishment thereof.

<sup>1</sup> A vote ‘Withheld’ is not a vote in law and is not counted in the calculation of the proportion of votes ‘For’ and ‘Against’ a resolution.

9. To authorise the Directors of the Company to allot shares and to grant rights to subscribe for shares in the Company.

### **Special Resolutions**

10. To authorise the Directors of the Company to disapply pre-emption rights.
11. To authorise the Company to make market purchases of its ordinary shares.
12. To allow the Company to hold general meetings, other than Annual General Meetings, on not less than fourteen (14) days' notice.

Copies of all resolutions and all documents referred to above can be obtained by contacting: Mr John McNeil, Company Secretary, OPTOS PLC Queensferry House, Carnegie Campus, Enterprise Way, Dunfermline KY11 8GR Scotland UK or by telephone by calling +44 (0) 1383 843 337 or electronically from the Company's website at: <http://www.optos.com/en/Investors/Shareholder-Information/AGM/>

### **About Optos plc**

Optos plc is a leading retinal imaging company. Our vision is to be recognised as a leading provider of devices and solutions to ophthalmic professionals for improved patient care. Optos' core devices produce ultra wide-field, high resolution digital images of approximately 82% of the retina, something no other device is capable of doing in any one image. The images provide optometrists and ophthalmologists with enhanced clinical information which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers.

Optos has a range of medical devices that support different customer segments and patient levels: the P200 and 200Dx devices are concentrated on wellness screening carried out by optometrists and ophthalmologists in primary care; the P200C and 200Rx devices are designed to meet the need for more exacting clinical imaging capabilities and standards in secondary care within the ophthalmology market and at optometric practices that are clinically managing a patient base with advanced ocular disease; and the P200MA and 200Tx devices supports ophthalmologists and retinal specialists in the medical care market. Optos' product range has recently been expanded to include the AccuPen, PachPen and B-Scan handheld devices for glaucoma and tumour management. The acquisition of Opto Global, completed in December 2010, brings additional devices for both optometrist and ophthalmologist practices, and expand the geographic reach outside our core North American and European markets. For more information please visit [www.optos.com](http://www.optos.com)

### **Forward-Looking Statements**

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.